Our fully integrated protein manufacturing services covers all needs from initial process development to manufacturing at research, HQ and GMP grade.
Meet our team at the booth #130 during the 11th Protein & Antibody Engineering summit, in Lisbon (Portugal), November 18-22th, 2019.
Talk and poster presentations
AUDITORIUM III/IV – Nov. 21 – 12:15 Luncheon Presentation I: Establishment of a CHO Transient Expression Platform for Bispecific Fusion Protein Developability Assessment
Thibaut Angevin, PhD, Pieris Pharmaceuticals GmbH
Pieris Pharmaceuticals’ proprietary molecules, the Anticalin® proteins, are small therapeutics derived from human lipocalins. They can be genetically linked to antibodies to generate different bispecific fusion proteins. Those proteins display different developability profiles. Pieris’ developability assessment platform has been established in order to screen bispecific constructs at an early stage, with an aim of identifying candidates that are best suited for advancement to stable cell line development or further optimization of such constructs.
57A. Development of an Advanced CHO Cell Expression System for Increased Transient Protein Production; Presented by Cassie-Marie P.
105B. Addressing Large-Scale Therapeutic Virus Production Using High Quality Grade PEI-Based Transfection Reagents; Presented by Jean-Thomas I.
The convention will take place at the Lisbon Congres Center:
Praça Indústrias 1, 1300-307 Lisboa, Portugal.